Congress Plans to Keep NCI Operating at FY2006 Budget

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 1
Volume 16
Issue 1

Congress adjourned and retreated from the nation's capital in early December without passing 9 of the 11 fiscal year (FY) 2007 appropriations bills, including that of the Department of Health and Human Services.

WASHINGTON—Congress adjourned and retreated from the nation's capital in early December without passing 9 of the 11 fiscal year (FY) 2007 appropriations bills, including that of the Department of Health and Human Services. The House and Senate did pass a continuing resolution enabling the affected federal departments and agencies to continue operating at FY2006 budget levels until February 1, 2007. And within days, leaders of the incoming Democratic-controlled Congress announced they would extend the current budget levels through FY2007, which ends September 30, 2007.

"While the results will be far from ideal, this path provides the best way to dispose of the unfinished business quickly, and allow governors, state, and local officials, and families to finally plan for the coming year with some knowledge of what the federal government is funding," Rep. David Obey (D-Wis) and Sen. Robert C. Byrd (D-WVa), chairmen of the House and Senate Appropriations Committees, said in a statement.

The decision left the National Institutes of Health (NIH) and the National Cancer Institute (NCI) in better financial shape than they would have been had Congress passed the FY2007 budget requested by President Bush. But it also meant another year of fewer real dollars with which to fund research and operate the NIH components.

Rep. Obey and Sen. Byrd indicated that Congress will make some monetary adjustments in the joint resolution that will extend the FY2006 budget as a way to address specific needs within some departments and agencies. But whether the NHI and NCI budgets will benefit remained an open question.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content